Kieron Dunleavy1, Michelle A Fanale2, Jeremy S Abramson3, Ariela Noy4, Paolo Fabrizio Caimi5, Stefania Pittaluga6, Samir Parekh7, Ann Lacasce3, John W Hayslip8, Deepa Jagadeesh9, Sunil Nagpal10, Mary Jo Lechowicz11, Rakesh Gaur12, Andrea Lucas1, Christopher Melani1, Mark Roschewski1, Seth M Steinberg13, Elaine S Jaffe6, Brad Kahl14, Jonathan W Friedberg15, Richard F Little16, Nancy L Bartlett14, Wyndham H Wilson17. 1. Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. 2. MD Anderson Cancer Center, Houston, TX, USA. 3. Massachusetts General Hospital and Dana Farber Cancer Institute, Boston, MA, USA. 4. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Case Western Reserve University, Cleveland, Ohio, USA. 6. Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA. 7. Hess Center for Science and Medicine, New York, NY, USA. 8. University of Kentucky, Lexington, KY, USA. 9. Cleveland Clinic, Cleveland, Ohio, USA. 10. West Michigan Cancer Center, Kalamazoo, MI, USA. 11. Emory University, Atlanta, GA, USA. 12. Saint Luke's, Kansas City, KS, USA. 13. Center for Cancer Research, and Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD, USA. 14. Washington University, St Louis, MO, USA. 15. University of Rochester, Rochester, NY, USA. 16. Cancer and Therapeutic Evaluation Program, National Cancer Institute, Bethesda, MD, USA. 17. Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. Electronic address: wilsonw@mail.nih.gov.
Abstract
BACKGROUND: MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment. We aimed to determine the outcome of dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R), an intensive infusional treatment regimen, in untreated aggressive B-cell lymphoma with MYC rearrangement. METHODS: We present the final analysis of a prospective, multicentre, single-arm, phase 2 study of DA-EPOCH-R in patients with untreated aggressive B-cell lymphoma with MYC rearrangement. DA-EPOCH-R was scheduled to be administered with CNS prophylaxis for six cycles. Primary endpoints included event-free and overall survival. This study is registered with ClinicalTrials.gov (NCT01092182). FINDINGS: 53 patients were enrolled, with median age of 61 years (range 29-80; IQR 50-70); 43 (81%) patients had stage III-IV disease and 26 (49%) had high-intermediate or high international prognostic index (IPI) scores. 19 patients had confirmed MYC rearrangement alone (single-hit) and 24 also had rearrangement of BCL2, BCL6, or both (double-hit), with similar characteristics between these two groups. After a median follow-up of 55·6 months (IQR 50·5-61·1), 48-month event-free survival was 71·0% (95% CI 56·5-81·4) and 48-month overall survival was 76·7% (95% CI 62·6-86·1) for all patients. Toxicity included grade 4 neutropenia in 160 (53%) of 301 cycles, grade 4 thrombocytopenia in 40 (13%) cycles, and any grade of fever with neutropenia in 56 (19%) cycles. There were three treatment-related deaths (all infections). INTERPRETATION: In this study, DA-EPOCH-R produced durable remission in patients with MYC-rearranged aggressive B-cell lymphomas and should be considered for the treatment of these diseases. FUNDING: Cancer Trials Support Unit and Center for Cancer Research of the National Cancer Institute and Genentech.
BACKGROUND:MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment. We aimed to determine the outcome of dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R), an intensive infusional treatment regimen, in untreated aggressive B-cell lymphoma with MYC rearrangement. METHODS: We present the final analysis of a prospective, multicentre, single-arm, phase 2 study of DA-EPOCH-R in patients with untreated aggressive B-cell lymphoma with MYC rearrangement. DA-EPOCH-R was scheduled to be administered with CNS prophylaxis for six cycles. Primary endpoints included event-free and overall survival. This study is registered with ClinicalTrials.gov (NCT01092182). FINDINGS: 53 patients were enrolled, with median age of 61 years (range 29-80; IQR 50-70); 43 (81%) patients had stage III-IV disease and 26 (49%) had high-intermediate or high international prognostic index (IPI) scores. 19 patients had confirmed MYC rearrangement alone (single-hit) and 24 also had rearrangement of BCL2, BCL6, or both (double-hit), with similar characteristics between these two groups. After a median follow-up of 55·6 months (IQR 50·5-61·1), 48-month event-free survival was 71·0% (95% CI 56·5-81·4) and 48-month overall survival was 76·7% (95% CI 62·6-86·1) for all patients. Toxicity included grade 4 neutropenia in 160 (53%) of 301 cycles, grade 4 thrombocytopenia in 40 (13%) cycles, and any grade of fever with neutropenia in 56 (19%) cycles. There were three treatment-related deaths (all infections). INTERPRETATION: In this study, DA-EPOCH-R produced durable remission in patients with MYC-rearranged aggressive B-cell lymphomas and should be considered for the treatment of these diseases. FUNDING: Cancer Trials Support Unit and Center for Cancer Research of the National Cancer Institute and Genentech.
Authors: Wyndham H Wilson; Sin-Ho Jung; Pierluigi Porcu; David Hurd; Jeffrey Johnson; S Eric Martin; Myron Czuczman; Raymond Lai; Jonathan Said; Amy Chadburn; Dan Jones; Kieron Dunleavy; George Canellos; Andrew D Zelenetz; Bruce D Cheson; Eric D Hsi Journal: Haematologica Date: 2011-12-01 Impact factor: 9.941
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Sietse M Aukema; Reiner Siebert; Ed Schuuring; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Evert-Jan Boerma; Philip M Kluin Journal: Blood Date: 2010-11-30 Impact factor: 22.113
Authors: A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt Journal: Nature Date: 2000-02-03 Impact factor: 49.962
Authors: Sharon Barrans; Simon Crouch; Alex Smith; Kathryn Turner; Roger Owen; Russell Patmore; Eve Roman; Andrew Jack Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Upendra Hegde; Armando Filie; Richard F Little; John E Janik; Nicole Grant; Seth M Steinberg; Kieron Dunleavy; Elaine S Jaffe; Andrea Abati; Maryalice Stetler-Stevenson; Wyndham H Wilson Journal: Blood Date: 2004-09-09 Impact factor: 22.113
Authors: Kerry J Savage; Nathalie A Johnson; Susana Ben-Neriah; Joseph M Connors; Laurie H Sehn; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne Journal: Blood Date: 2009-08-24 Impact factor: 22.113
Authors: Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt Journal: N Engl J Med Date: 2002-06-20 Impact factor: 91.245
Authors: Wyndham H Wilson; Kieron Dunleavy; Stefania Pittaluga; Upendra Hegde; Nicole Grant; Seth M Steinberg; Mark Raffeld; Martin Gutierrez; Bruce A Chabner; Louis Staudt; Elaine S Jaffe; John E Janik Journal: J Clin Oncol Date: 2008-03-31 Impact factor: 44.544
Authors: Nancy L Bartlett; Wyndham H Wilson; Sin-Ho Jung; Eric D Hsi; Matthew J Maurer; Levi D Pederson; Mei-Yin C Polley; Brandelyn N Pitcher; Bruce D Cheson; Brad S Kahl; Jonathan W Friedberg; Louis M Staudt; Nina D Wagner-Johnston; Kristie A Blum; Jeremy S Abramson; Nishitha M Reddy; Jane N Winter; Julie E Chang; Ajay K Gopal; Amy Chadburn; Susan Mathew; Richard I Fisher; Kristy L Richards; Heiko Schöder; Andrew D Zelenetz; John P Leonard Journal: J Clin Oncol Date: 2019-04-02 Impact factor: 44.544
Authors: Fabiola Valvert; Oscar Silva; Elizabeth Solórzano-Ortiz; Maneka Puligandla; Marcos Mauricio Siliézar Tala; Timothy Guyon; Samuel L Dixon; Nelly López; Francisco López; César Camilo Carías Alvarado; Robert Terbrueggen; Kristen E Stevenson; Yasodha Natkunam; David M Weinstock; Edward L Briercheck Journal: Blood Adv Date: 2021-05-25
Authors: Mary-Elizabeth M Percival; Ryan C Lynch; Anna B Halpern; Mazyar Shadman; Ryan D Cassaday; Chaitra Ujjani; Andrei Shustov; Yolanda D Tseng; Catherine Liu; Steven Pergam; Edward N Libby; Bart L Scott; Stephen D Smith; Damian J Green; Ajay K Gopal; Andrew J Cowan Journal: JCO Oncol Pract Date: 2020-05-05
Authors: Pallawi Torka; Shalin K Kothari; Suchitra Sundaram; Shaoying Li; L Jeffrey Medeiros; Emily C Ayers; Daniel J Landsburg; David A Bond; Kami J Maddocks; Anshu Giri; Brian Hess; Luu Q Pham; Ranjana Advani; Yang Liu; Stefan Klaus Barta; Julie M Vose; Michael C Churnetski; Jonathon B Cohen; Madelyn Burkart; Reem Karmali; Joanna Zurko; Amitkumar Mehta; Adam J Olszewski; Sarah Lee; Brian T Hill; Timothy F Burns; Frederick Lansigan; Emma Rabinovich; David Peace; Adrienne Groman; Kristopher Attwood; Francisco J Hernandez-Ilizaliturri Journal: Blood Adv Date: 2020-01-28
Authors: Ramya Ramaswami; Kathryn Lurain; Mark N Polizzotto; Irene Ekwede; Kirsta Waldon; Seth M Steinberg; Ralph Mangusan; Anaida Widell; Adam Rupert; Jomy George; Priscila H Gonçalves; Vickie A Marshall; Denise Whitby; Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe; Richard F Little; Thomas S Uldrick; Robert Yarchoan Journal: Blood Adv Date: 2021-03-23